Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer

A technology for prostate cancer and Listeria, which is applied in the field of combination therapy for the treatment of cancer and the antagonist of programmed death 1 protein, which can solve the problems of weakening tumor immune response, weakening T cell activation and immune surveillance, etc.

Inactive Publication Date: 2017-08-01
ADVAXIS +1
View PDF35 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, PD-L1-expressing tumor cells have been proposed to interact with PD-1-expressing T cells to attenuate T cell activation and evade immune surveillance, resulting in a weakened immune response to tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
  • Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
  • Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

example

[0422] A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and in Combination with Pembrolizumab (MK-3475) in Patients with Previously Treated Metastatic Castration-Refractory Prostate Cancer (mCRPC)

[0423] This is a Phase 1-2, open-label, multicenter, nonrandomized, two-part study in patients with metastatic castration-resistant prostate cancer (mCRPC). Part A of the study will be an open-label, Phase 1, multicenter, non-randomised, dose-determining trial of ADX31-142 monotherapy in subjects with metastatic castration-resistant prostate cancer (mCRPC). Part B of the study will be an open-label, Phase 1-2, multicenter, non-randomized, dose-determining trial of ADXS31-142 in combination with pembrolizumab (MK-3475) in subjects with mCRPC. Figure 10 A schematic diagram of the monotherapy and combination portions of the study is shown.

[0424] Purpose:

[0425] Part A: Assess the safety and tolerability of ADXS31-142 monotherapy and select the recommended Phase...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

Description

technical field [0001] The present invention relates to combination therapies useful in the treatment of cancer. In particular, the present invention relates to the combination of an antagonist of programmed death 1 protein (PD-1) and a live attenuated recombinant Listeria strain for the treatment of prostate cancer, the live attenuated recombinant Listeria strain comprising A fusion protein formed by fusing the polypeptide of the PEST sequence or the peptide containing the PEST sequence to a tumor-associated antigen. Background technique [0002] PD-1 is considered to play an important role in immune regulation and maintenance of peripheral tolerance. PD-1 is moderately expressed on unexposed T, B, and NKT cells and is upregulated by T / B cell receptor signaling on lymphocytes, monocytes, and myeloid cells (1). [0003] Two known ligands of PD-1, PD-L1 (B7-H1) and PD-L2 (B7-DC), are expressed in human cancers arising in various tissues. In large sample groups such as ovar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02A61K35/74A61K39/12A61P35/00
CPCA61K2039/522A61P35/00A61K39/39558A61K2039/523A61K2039/572A61K39/001194A61K2039/884A61K39/0011A61K2300/00A61K35/74A61P13/08C12N1/205A61K2039/545
Inventor R·佩蒂D·J·毛罗R·F·佩里尼
Owner ADVAXIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com